Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an update.
Xvivo Perfusion AB reported a challenging first half of 2025, with net sales declining by 15% in SEK and 9% in local currencies. The company’s thoracic and services segments experienced negative growth, while the abdominal segment showed a positive sales increase. Despite a stable gross margin, the company faced a significant drop in operating income and net profit, largely due to currency effects and strategic investments in R&D and inventory. These financial results reflect the company’s ongoing efforts to adapt to market conditions and invest in future growth, though they pose challenges for stakeholders in the short term.
The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Xvivo Perfusion AB operates in the medical technology industry, specializing in advanced solutions for organ transplantation. The company focuses on developing and marketing systems and consumables for preserving, transporting, and assessing organs outside the body, with particular emphasis on thoracic and abdominal organs.
Average Trading Volume: 82,959
Current Market Cap: SEK9.02B
See more data about XVIVO stock on TipRanks’ Stock Analysis page.